Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: after stuttering and stumbling, demanding upside motion

July 27, 2018 7:52am

The sector will also be keeping a close eye on the shares of gene editing companies

The IBB signals some hope, indicating a +0.13% upside in Friday’s pre-market;

Let’s hope the weekend is better than this week has been

Pre-open indications: 2 BUYs, 3 SELLs and 1 trade

RMi reports pre-open indications that shed light on share pricing events and today’s session values!

Want to know WHY, subscribe!

U.S. stock index futures are ready and set for gain

Dow futures are UP +0.10% (+26 points) and NASDAQ futures are UP +0.17% (+13 points)

U.S. stock index futures ticked higher ahead of Friday's open, as investors geared up for fresh gross domestic product (GDP) figures.

Europe markets set for fourth week of gains

Asian stocks closed mixed with Australia outperforming its peers in the region.

Data docket: he advance GDP reading for the second quarter is due out at 8:30 a.m. ET, which should offer investors some indication as to how the U.S. economy has been performing. Consumer sentiment for July is due out at 10 a.m. ET.

Henry’omics:

There has been 6 negative closes in the past 9 sessions; it’s time for the oversold to start being overbought!

For the week as a whole, the Dow was looking at a gain of 1.9%, the S&P 500 a gain of 1.3%, with the NASDAQ trailing with a 0.4% rise, all as of Thursday’s close. Both the Dow and the S&P are on track for their fourth straight positive week, their longest such streak since January.

The weekend can’t come soon enough …

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a +0.13% upside in Friday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is NOT indicating in Friday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a+0.22% UPSIDE in Friday’s pre-open

From Thursday’s night’s newsletter: “a “craps” table sector with cold dice. The opening throw was down, the first hour flipped to the upside reversing to the downside at the mid-day and closed negative of my 45 covered companies.”

I always want to know what happened PRIOR to what might happen today – it sets a tone of consequence!

The iShares NASDAQ Biotechnology (IBB) was down -1.24% after Wednesday’s +1.11%, Tuesday’s -0.14%, Monday’s -0.06% and last Friday’s-0.08% … for a five session aggregate of -0.47% … UPSIDE needed!

Last week had 3 negative closes, 2 positive sessions and started this week, Monday and Tuesday experiencing negative sessions with Wednesday beating the curse to turn positive but, Thursday returning to the downside;

For the month so far, July has experienced 11 positive closes, 7 negative closes and 1 holiday;

Of the 45 companies covered on Thursday; 26 downside equities finished in a range of -$0.03 (HSGX) to -$4.69 (SAGE) while the 14 upside equities oscillated from +$0.0 () to $8.85 () with 5 flat closes;

Thursday’s gainers ranged from +0.10% <BMRN +$0.10 > to +10.85% <MDXG +$0.47> in 14 equities;

Thursday’s decliners ranged from -0.11% <FATE -$0.01 > to -6.87% < HSGX -$0.16 > in 28 equities;

Companies in my headlights – It’s your decision; I provide the idea and context:

CRISPR Therapeutics (CSP) closed down $1.09 to $49.77 after Wednesday’s-$0.99 to $50.82, Tuesday’s -$5.46 to $51.81 post Monday’s $57.72 - Maintaining SELL;

Editas Medicine (EDIT) closed down -$0.28 to $311.54 after Wednesday’s -$0.64 to $31.82, Tuesday’s -$2.91 to $32.46 post Monday’s $35.37 - Maintaining SELL;

Intellia Therapeutics (NTLA) closed down -$0.68 to $27.53 after Wednesday’s -$0.28 to $28.21, Tuesday’s -$1.96 to $28.49 post Monday’s $30.45 - Trade;

Fate Therapeutics (FATE) closed down -$0.01 to $9.26 after Wednesday’s -$0.46 to $9.27, Tuesday’s -$1.135 to $9.735 post Monday’s $10.87. FATE has been in MY oversold list having started July at $11.77, having seen a high of $12.44 and a low of $9.735 – Oversold - Maintaining BUY;

MiMedx Group (MDXG) closed up +$0.47 to $4.80 and has a downside aftermarket indication of -$0.42 or -8.75% as news of that it faces a possible delisting of its shares as MDXG would be unable to bring its SEC filings into compliance. MDXG plans to request a hearing to appeal the decision. MDXG citing a letter (7/10/18) received from NASDAQ, that any hearing would likely take place 30 to 45 days after the hearing request – SELL;

Solid Biosciences (SLDB) closed up +$0.86 to $38.75 after Wednesday’s -$1.35 to $37.89 following Tuesday’s $39.24 and Monday’s $40.17, last Friday’s $43.11 with a positive aftermarket indication of +$0.65 or +1.68%. Sarepta Therapeutics (SRPT) announced a manufacturing-related hold Wednesday on its P1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy but SLDB could benefit from SRPT’s delay.- SELL to BUY;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

10 hours 6 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.